Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov Sells 2,431 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov sold 2,431 shares of the business’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $6.13, for a total transaction of $14,902.03. Following the transaction, the chief executive officer now owns 187,471 shares of the company’s stock, valued at $1,149,197.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Monday, June 3rd, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.76, for a total value of $16,433.56.
• On Wednesday, May 1st, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.11, for a total value of $22,146.41.
• On Friday, April 5th, Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.75, for a total value of $476,225.00.
• On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.78, for a total value of $437,495.52.

Fennec Pharmaceuticals Price Performance

Fennec Pharmaceuticals stock opened at $6.03 on Thursday. The company has a debt-to-equity ratio of 9.86, a current ratio of 6.93 and a quick ratio of 6.72. The stock has a market capitalization of $164.74 million, a PE ratio of 201.00 and a beta of 0.29. The business has a 50 day simple moving average of $7.40 and a 200-day simple moving average of $9.22. Fennec Pharmaceuticals Inc has a 12 month low of $5.97 and a 12 month high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings results on Tuesday, May 14th. The company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.08). Fennec Pharmaceuticals had a net margin of 6.33% and a negative return on equity of 39.41%. The company had revenue of $25.38 million during the quarter, compared to analyst estimates of $10.46 million. During the same period in the prior year, the business posted ($0.23) EPS. On average, analysts anticipate that Fennec Pharmaceuticals Inc will post 0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Fennec Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of FENC. Tower Research Capital LLC TRC boosted its stake in Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock worth $34,000 after buying an additional 1,578 shares during the last quarter. Jump Financial LLC purchased a new position in shares of Fennec Pharmaceuticals during the 4th quarter worth $158,000. BNP Paribas Financial Markets boosted its position in shares of Fennec Pharmaceuticals by 67.7% during the 1st quarter. BNP Paribas Financial Markets now owns 32,769 shares of the company’s stock valued at $364,000 after acquiring an additional 13,223 shares during the last quarter. Eudaimonia Advisors LLC grew its holdings in shares of Fennec Pharmaceuticals by 90.8% in the fourth quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock valued at $367,000 after purchasing an additional 15,556 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in shares of Fennec Pharmaceuticals by 71,275.0% in the first quarter. Russell Investments Group Ltd. now owns 34,260 shares of the company’s stock valued at $381,000 after purchasing an additional 34,212 shares during the period. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on FENC shares. HC Wainwright cut their target price on shares of Fennec Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, May 15th. Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Fennec Pharmaceuticals in a report on Tuesday, May 14th. Finally, Craig Hallum lowered their target price on shares of Fennec Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 15th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.